myotwin is developing a data-driven platform that combines human 3D heart tissue with precise measurement technology and digital analysis to test active ingredients for heart medications more realistically and reliably. The technology makes it possible to evaluate human heart muscle tissue grown in the laboratory in detail, enabling better predictions to be made about the efficacy and safety of new substances. The platform is already being used in contract research projects with pharmaceutical and biotech companies and forms the basis for a digital “heart twin” that supports personalized therapy approaches with the help of machine learning. Myotwin is thus creating a holistic ecosystem for preclinical cardiac drug development and an important key technology at the interface between biotechnology and digitalization.
| 10/2023 | Company founded | |
| 10/2025 | Accepted for the HTI BioIntelligence Programme |
"The HTI programmes have been great in supporting us to build a comprehensive network. We were able to successfully exchange ideas with many exciting startups. But at least as important was networking with investors and the great progress we made in our financings rounds. The HTI Team has always convinced us with their innovative and professional advice and their great commitment. Without the HTI BioIntelligence, such professional management of the funding would have not been possible. Our mindset has been sharpened in a streamlined way by attending the HTI events. It made us start our entrepreneurial journey as Allogenetics team & we felt tremendously supported to achieve our milestones. We look forward to our continued collaboration!"
Rainer Blasczyk & Julian Meckfessel of Allogenetics